
1. j clin microbiol. 2005 may;43(5):2133-40.

evaluation cobas hepatitis c virus (hcv) taqman analyte-specific reagent
assay comparison cobas amplicor hcv monitor v2.0 versant hcv bdna 
3.0 assays.

konnick eq(1), williams sm, ashwood er, hillyard dr.

author information: 
(1)arup institute clinical experimental pathology, 500 chipeta way, salt 
lake city, ut 84108, usa. konnice@aruplab.com

performance characteristics cobas hepatitis c virus (hcv) taqman
analyte-specific reagent (tm-asr) assay using qiagen biorobot 9604 rna
extraction evaluated compared cobas amplicor hcv monitor v2.0
(amplicor) versant hcv bdna 3.0 (versant) assays using clinical samples.
calibration tm-asr using armored rna allowed determination distribution
of hcv rna clinical samples, using 22,399 clinical samples. limit of
detection, linearity, inter- intraassay assay precision determined
for tm-asr assay using multiple clinical specimen panels across multiple
determinations. genotype specificity tm-asr assay determined using
samples different hcv rna genotypes evaluated compared against
predetermined results. contamination control tm-asr assay evaluated
using pools hcv rna-positive -negative samples tested checkerboard
pattern 12 runs 96 samples. correlation tm-asr, amplicor, and
versant assays determined using 100 paired clinical samples deming
regression analysis. tm-asr performed well respect linearity,
precision, contamination control. correlation tm-asr the
amplicor versant assays poor, large differences assay
results individual samples. calibration tm-asr assay armored rna 
allowed wide dynamic range description distribution hcv rna
in clinical samples.

doi: 10.1128/jcm.43.5.2133-2140.2005 
pmcid: pmc1153797
pmid: 15872232  [indexed medline]

